

Supplemental material

Supplemental Table. Patient Cardiovascular History by Study – Phase 3 Trials

CV Diagnosis/Event	HoFH		Severe HC		HeFH with CAD*		HC at high risk for CHD	
	n (%)		n (%)		n (%)		n (%)	
	PBO (n=17)	MIPO (n=34)	PBO (n=18)	MIPO (n=39)	PBO (n=41)	MIPO (n=83)	PBO (n=50)	MIPO (n=101)
Hypertension	2 (11.8)	3 (8.8)	-	-	-	-	-	-
Revascularization	4 (23.5)	10 (29.4)	-	-	-	-	-	-
Atherosclerotic disease	11 (64.7)	19 (55.9)	-	-	-	-	-	-
Aortic valve stenosis	10 (58.8)	16 (47.1)	-	-	2 (4.9)	5 (6.0)	-	-
Aortic valve replacement	1 (5.9)	3 (8.8)	-	-	-	-	-	-
Angina	-	-	4 (22.2)	11 (28.2)	8 (19.5)	27 (32.5)	5 (10.0)	9 (8.9)
Cardiovascular Heart Disease	-	-	13 (72.2)	28 (71.8)	-	-	21 (42.0)	50 (49.5)
MI	-	-	3 (16.7)	8 (20.5)	11 (26.8)	34 (41.0)	11 (22.0)	17 (16.8)
CABG	-	-	6 (33.3)	12 (30.8)	22 (53.6)	37 (44.6)	4 (8.0)	14 (13.9)
PCI	-	-	1 (5.6)	4 (10.3)	13 (31.7)	25 (30.1)	4 (8.0)	18 (17.8)
CAD w/out event	-	-	5 (27.8)	11 (28.2)	7 (17.1)	19 (22.9)	6 (12.0)	12 (11.9)
Peripheral Artery Disease	-	-	2 (11.1)	1 (2.6)	6 (14.6)	8 (9.6)	1 (2.0)	5 (5.0)
Abdominal Aortic Aneurysm	-	-	0 (0.0)	1 (2.6)	-	-	1 (2.0)	0 (0.0)
Carotid Artery Disease	-	-	5 (27.8)	6 (15.4)	-	-	1 (2.0)	8 (7.9)

--Data not reported. PBO=Placebo; MIPO=mipomersen; * By definition all patients in this cohort had a history of CAD, data based on safety set analysis. (The data from this study is based on the safety analysis set which includes 1 more subject in the MIPO arm than the full analysis set that the other studies are based on).